secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000875320-24-000221
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B
------------------------------------------------------------------------------

- GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.
- FY 2024 product revenue guidance raised to $10.8-10.9B from $10.65-10.85B.
- PDUFA dates: vanzacaftor triple Jan 2, 2025; suzetrigine Jan 30, 2025; both Priority Review.
- Three programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, VX-880 in T1D.
- CASGEVY revenue from first infused patient; 45 ATCs activated globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/0000875320-24-000221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/vrtx-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer